SNDX vs. AGIO, SDGR, CPRX, GPCR, AMRX, GERN, NAMS, SUPN, AVDL, and HRMY
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Agios Pharmaceuticals (AGIO), Schrödinger (SDGR), Catalyst Pharmaceuticals (CPRX), Structure Therapeutics (GPCR), Amneal Pharmaceuticals (AMRX), Geron (GERN), NewAmsterdam Pharma (NAMS), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.
Agios Pharmaceuticals currently has a consensus target price of $33.50, suggesting a potential upside of 6.38%. Syndax Pharmaceuticals has a consensus target price of $34.42, suggesting a potential upside of 63.42%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Syndax Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -1,312.64%. Syndax Pharmaceuticals' return on equity of -38.08% beat Agios Pharmaceuticals' return on equity.
Agios Pharmaceuticals received 114 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 67.90% of users gave Agios Pharmaceuticals an outperform vote while only 64.54% of users gave Syndax Pharmaceuticals an outperform vote.
In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 2 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.38 beat Syndax Pharmaceuticals' score of -0.08 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Agios Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Summary
Syndax Pharmaceuticals beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
